Just read the two abstracts of the EASL conference.
Gilead research results are presented for hbeag negative, as well as for hbeag positive CHB, for 48 out of 96 weeks of treatment.
If presented results are true, it is clear that for hbeag negative CHB, TAF seems to be superior option compared to TDF. Compared to TDF, TAF resulted in significantly higher percentage of patients having normalised ALT after 48 weeks of treatment (50% vs 32%), significantly less loss of eGFR (loss of 1.4 vs 4.7), and significanlty less loss of bone mineral density.
The study is continuing for another 48 weeks...